The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Current health news covers Gilead's withdrawal of a cancer drug, Texas' lawsuit against a doctor for providing ...

(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

Antibody-drug Conjugates in Oncology Pipeline Report Introduction 2. Antibody-drug Conjugates in Oncology Pipeline Report Executive Summary ...

Israelis Were Surprised to Discover Sinwar’s Body After Shooting Stopped The soldiers who killed Yahya Sinwar, a major target of Israel’s military campaign in Gaza, had not expected to run ...